Pds Biotechnology Corporation Stock Price, News & Analysis

PDS Biotechnology Corporation (Nasdaq: PDSB) will release its Q2 2021 financial results on August 12, 2021, before the market opens. Following the release, a conference call will be held at 8:00 am ET to review the results and provide a business update. PDS Biotech is focused on developing novel cancer therapies using its proprietary Versamune T-cell activating technology, with its lead product PDS0101 currently in three Phase 2 clinical studies targeting HPV-associated cancers. Interim results have shown strong efficacy in advanced, treatment-resistant cancers.

PDS Biotechnology Corporation (Nasdaq: PDSB) was added to the Russell Microcap® Index as of June 28, 2021. This inclusion enhances visibility among investors and confirms the company's progress in developing its lead HPV-cancer immunotherapy, PDS0101, currently in three Phase 2 trials. The Russell indexes, which benchmark approximately $10.6 trillion in assets, inform investment strategies globally. Dr. Frank Bedu-Addo emphasized that this recognition underscores the potential to improve cancer therapy effectiveness and increase shareholder value.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced the closing of its public offering of 6,088,235 shares at $8.50 each, raising approximately $51.7 million before expenses. The offering saw participation from insiders, including board members and executives. Cantor Fitzgerald & Co. managed the offering, which was made under a previously filed registration statement. PDS Biotech focuses on developing cancer immunotherapies using its proprietary Versamune® technology, with ongoing clinical studies for its lead product, PDS0101, in various cancers.

PDS Biotechnology Corporation (Nasdaq: PDSB) announced a public offering of 5,294,118 shares at a price of $8.50 per share, aiming to raise approximately $45.0 million before expenses. The offering is expected to close around June 17, 2021, with Cantor Fitzgerald & Co. as the sole bookrunner. Proceeds will support the clinical pipeline development and general corporate needs. Additionally, underwriters can purchase an extra 794,117 shares within 30 days. This follows a previous shelf registration effective since July 31, 2020.

PDS Biotechnology Corporation (PDSB) announced an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The offering is subject to market conditions, with no guarantee on completion or specific terms. Proceeds from this offering will support the development of its clinical pipeline and general corporate purposes, including working capital. The registration statement for this offering was effective as of July 31, 2020, with preliminary prospectus materials filed with the SEC.

PDS Biotechnology Corporation (Nasdaq: PDSB) will host an Oncology R&D Day on June 16, 2021, at 8:00 am ET, aimed at analysts, investors, and the scientific community. The event will showcase advancements in the company's cancer immunotherapy pipeline utilizing the proprietary Versamune^® technology. Key presentations will feature several experts, including company executives and researchers from the National Cancer Institute. A live webcast will be available, along with presentations published on the company’s website the following day.

PDS Biotechnology Corporation announced interim data from its Phase 2 trial (NCT04287868) of PDS0101 (Versamune®-HPV16) at the ASCO 2021 Annual Meeting. The trial shows promising results: 83% tumor reduction in checkpoint inhibitor naïve patients and 58% in checkpoint inhibitor refractory patients. Among the 25 patients, 100% failed chemotherapy, 96% failed both chemotherapy and radiation, and 56% were checkpoint inhibitor refractory. Notably, the overall response rate compares favorably with current standards, highlighting PDS0101's potential for advanced HPV16-associated cancers.

PDS Biotechnology Corporation (Nasdaq: PDSB) will join the Russell Microcap Index effective June 28, following the annual reconstitution. This inclusion enhances the company's visibility within the investment community and offers advantages for shareholder value. The company is progressing its Phase 2 clinical programs, especially for its lead product, PDS0101, targeting HPV-associated cancers. With approximately $10.6 trillion in assets benchmarked to Russell indexes, this membership provides a significant opportunity for PDSB to attract new investments.